Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3659600 A
Publication typeGrant
Publication dateMay 2, 1972
Filing dateFeb 24, 1970
Priority dateFeb 24, 1970
Publication numberUS 3659600 A, US 3659600A, US-A-3659600, US3659600 A, US3659600A
InventorsMerrill Edward W
Original AssigneeCharles River Foundation The, Estin Hans H, Leonard W Cronkhite Jr, William W Wolbach
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Magnetically operated capsule for administering drugs
US 3659600 A
Abstract
An implantable capsule for delivering drugs when subjected to a magnetic force outside the body and controlled by the patient. The capsule has a means movable under a magnetic force to effect contact of the medicament in the capsule with a drug-permeable wall. When contacted, the drug diffuses through the wall into the body. When it is desired to cease drug administration, the capsule is subjected to an opposite magnetic force to seal the permeable wall from contact with the drug.
Images(1)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

I United States Patent 1 1 3,659,600 Merrill [451 May 2, 1972 54] MAGNETICALLY OPERATED CAPSULE 3,485,235 12 1969 Fetson ..12s 2 R FOR ADMINISTERING DRUGS 3,118,439 1/1964 Perrenoud... ..128/2 R 3,419,008 12/1968 Plishnerl... .....128/1 R X [72] Invent": Edwm cambndge' Mass- 3,093,831 6/1963 Jordan ..l28/260 x [73] Assignee: Hans H. Estin, Leonard W. Cronkhite, Jr.

and William W. Wolbach, Trustees of the Primary Examiner-Richard A. Gaudet Charles River Foundation, Boston, Mass. Assistant Examiner-J. B. Mitchell [22] Filed: 24, 1970 Attorney-Kenway, Jenney & lelildreth [21] Appl. No.: 13,278 57 ABST CT An implantable capsule for delivering drugs when subjected to [52] [1.5-

a magnetic force outside the and ontrolled the pa. ll!!- Cl- ..A6lm tient The ca ule has a means movable under a magnetic [58] held Search "128/1721 force to effect contact of the medicament in the capsule with a 128/11 2 P drug-permeable wall. When contacted, the drug diffuses through the wall into the body. When it is desired to cease [56] References Cited drug administration, the capsule is subjected to an opposite UNITED STATES PATENTS magnetic force to seal the permeable wall from contact with the drug. 3,315,660 4/1967 Abella ..128/2 R Long, Jr. et a1. ..128/272 X 3 Claims, 2 Drawing Figures Patented May 2, 1972 3,659,600

FIG. I

FIG. 2

INVENTOR EDWARD W. MERRILL- r $1M 7? ATTORNEYS MAGNETICALLY OPERATED CAPSULE FOR ADMINISTERING DRUGS This invention relates to a capsule activated by magnetic force to release a medicament.

Capsules implanted into the human body to administer long-acting drugs such as regulatory hormones over long periods have in general been simple passive systems. The drug diffuses from the capsule interior through the capsule walls into the body at a rate governed exclusively by the wall thickness and the concentration of the drug. No independent control is imposed either by the exterior chemical milieu of the patient or by any action on the part of the patient, to regulate the rate of drug diffusion or when administration is initiated and ceased. Since the patient either does not have a continuous need for the drug but usually has a need governed by a convenient schedule or when physiological sensation informs him of the need for the drug, it would be highly desirable to provide a drug-filled capsule implanted into the patient for the purpose of administering the drug on a non-continuous basis and/or on any convenient schedule desired by the patient through the use of means solely within his control.

The present invention provides capsules suitable for implantation into the body for administering a drug from the interior of the implanted capsule to the body by subjecting the capsule to magnetic force from a source located outside of the body. When the magnetic force is applied from one direction, a magnetic means within the capsule is caused to move thereby effecting delivery of a quantity of a drug from a storage compartment in the capsule from which it diffuses through a permeable wall portion of the capsule into living tissue.

Only a portion of the capsule wall need be constructed of a material permeable to a drug contained in the capsule while the remainder of the capsule wall is non-permeable to the drug. A magnetically activatable means in the capsule is adapted to move within the capsule either linearly or rotationally under a magnetic force to provide or terminate contact of the drug-permeable wall portion and the drug in the capsule as desired. When the drug and permeable wall are brought into contact, the drug begins to difi'use into the permeable wall and thence, subsequently, into the body. When the drug and permeable wall are removed from contact, the permeable wall releases drugs already in it, at an ever decreasing rate, and finally is exhausted of drug. Administration of the drug can be controlled easily by the patient by positioning the source of the magnetic force outside the body to move the magnetically activatable means and provide or terminate contact of the drug and permeable wall for the period desired by the patient.

The process of this invention for administering drugs, and the capsule therefor provide substantial advantages over presently available means for administering drugs from an implanted capsule, in that administration is within theexclusive control of the patient. Furthermore, the present invention permits the administration of drugs from implanted capsules which drugs were previously administered by other means due to the need for non-continuous administration.

FIG. 1 is a sectional view of a cylindrical capsule of this invention especially suited for contraceptive drugs such as progestin, taken along the midplane coextensive with its major axis showing the magnetically operable means in two posi tions.

FIG. 2 is a sectional bottom view of a capsule of FIG. 1 taken along line 2-2 and provided with additional structural supports.

Referring to FIG. 1 the retaining capsule 1 having a cylindrical shape is defined by ends 2 and 3, non-permeable cylindrical wall 4 and permeable wall 5 supported on screen 6 to provide mechanical strength. The retaining capsule 1 contains a magnetic hollow piston 7, a spring 8 and either a drug solution or the drug itself. The spring 8, drug and piston 7 can be inserted into the capsule 1 by removing cap 3 and thereafter sealing the cap 3 in place. The spring 8, has a low spring constant which maintains the piston 7 against the end 2 in the rest state. When the capsule is subjected to a magnetic force from a source outside the body, the piston 7 is moved to a position 8 shown by the dotted lines. The piston movement compresses the spring 8, and, because piston 7 is hollow, the contained drug, drug solution, or drug suspension moves through the piston 7 and contacts permeable wall 5. The drug diffuses through the wall 5 at a diffusion rate controlled by the thickness of wall 5 and the concentration of the drug. The rate of administration of the drug is controlled by the surface area of wall 5 and the drug diffusion rate. When it is desired to stop drug administration, as for example, to turn off a contraceptive hormone in order to permit conception, the patient reverses the process, and magnetically attracts the piston 7 to position A which movement is assisted by spring 8. When the piston is in position A, the walls is effectively sealed from contact with the drug. Spring 8 maintains piston 7 in a fail-safe position; that is to say, unless a magnet force is intentionally applied to move piston 7, the neutral position of piston 7 is to seal the wall 5 from contact with the drug.

Referring to FIG. 2, the capsule of FIG. 1 is modified to include supports 10 extending between the end piece 2 and the wall 4 to provide a rigid support for membranes 5. The interior surface 11 of the supports 10 conform to that of the interior surfaces of end piece 2 and wall 4 to permit smooth and undisturbed movement of piston 7 and also to reduce the possibility of damaging wall 5. Any number of supports 10 can be used with 3, 4 or 6 being preferred.

The end pieces and rigid wall of the capsule are constructed of materials which are non-magnetic, and non-toxic, do not degrade the drug, have long durability in contact with body fluids and negligible permeability. Furthermore, any material used in the formation of the capsule must have the fundamental properties of high mechanical-strength against fracture by accidental blows. Suitable materials for use in the capsule are non-magnetic metals such as tantalum, non-magnetic stainless steels, platinum, or the like or non-metals such as polycarbonates or the like. The free moving piston 7 must be of ferromagnetic materials, and in general it must be coated to prevent its corrosion in or contamination of the contained drug or drug solution. The piston can be coated with ceramic enamels by high temperature fusion, organic enamels of high strength and abrasion resistance such as phenol-formaldehyde resin, or the like.

The permeable membrane is preferably made of a crosslinked elastomer or a network polymer in a swollen solvated state which is highly permeable to the drug. Generally speaking, polymers in their glassy state are not desirable for this purpose, because of their inordinately low permeability,-but cellulose acetate Loef type reverse osmosis membranes, suitably modified to increase pore size, may be used. The elastomeric material employed to form the permeable wall must be nontoxic, cross-linkable to the desired elastic modulus, inert to the drug and have a finite permeability to the contained drug to give accurate slow release of the drug into the body upon implantation. Non-toxic additives, usually employed in the elastomeric materials, may be employed include fillers such as silica or the like, provided only that the capsule retains its final shape after its processingand the drug can be diffused through the elastomer. For a lipid soluble medicament or drug, including steroid hormones such as the progestins, and estrogen, it is preferred to employ silicone rubbers i.e., organopolysiloxane wherein the organic groups attached is the silicon atom preferably methyl, phenyl, vinyl, or combinations thereof. This preference is because silicone rubbers have relative freedom from toxic products of vulcanization, and are inert as an implanted material.

In general, the permeable wall of the cylindrical capsule can beformed by compression moldingand vulcanization, or by an equivalent procedure so that'the wall material is crosslinked'while being contained between mating interior and exterior molds to produce a product having a smooth continuous surface co-extensive with the interior surface of the capsule. Cross-linkingcan-be efl'ected in any manner well known in the art, including ionizing radiation which is especially appropriate to silicone elastomers. After cross-linking, the permeable wall is treated to remove by-products of the crosslinking step, if any, which may be toxic or which may degrade the drug. Thus, for example, phenyl benzoate produced by thermal decomposition of benzoyl peroxide initiator can be removed by extraction. The membrane is bonded to the wall of the capsule in any convenient manner. Thus, the membrane can be molded and cross-linked while in contact with the nonpermeable capsule wall to thereby provide an effective seal. The surface of the wall also can be modified or coated with a material to effect a strong seal with the membrane. Thereafter, the decomposition products from the crosslinking step can be removed from the membrane prior to filling the capsule.

Once the cylindrical capsule has been filled with the drug,

the sliding piston and the retaining spring, it is convenient to seal the end plate 3 by some relatively permanent means, such as with a permanent non-toxic adhesives such as epoxy or by heat sealing the material if it be polymeric, such as a polycarbonate or the like.

It is essential that the sliding piston move freely but snugly within the capsule to provide efi'ective sealing or contact of the penneable wall and drug. The piston material or coating used on the piston shouldnot adhere to any of the surfaces with which it contacts and there must be geometric precision between the sliding piston and the interior surface of the capsule. The length of the sliding piston is significantly greater than the corresponding length of the permeable wall, so that when it is in the closed position leakage of the drug is minimized. Generally, the capsule is 4 to 15mm. long and 2 to mm. wide the piston being about 2.5mm. to 10mm. long. It is desirable to minimize the piston wall thickness to maximize the amount of drug in the capsule. While the capsule of this invention is described with reference to a magnetically operable means comprising a hollow piston, it is to be understood that the magnetically operable means can be of any geometric shape so that it moves freely but snugly within the capsule to provide eflective sealing of the drug and permeable wall and permits contact of the drug and permeable wall when desired.

When the drug is a solid rather than a liquid it is desirable to form a solution thereof with a solvent or a dispersion thereof in an inert carrier liquid. The solvent employed should dissolve the drug to afford the preparation of concentrated solution, and must be inert to both the drug and the elastomeric material. A suitable carrier liquid should be inert to the drug, and capable of suspending the drug when the drug is rendered into microparticles. Thus, ideally the carrier liquid has the same density as the drug. Accordingly, the choice of solvent and elastomer is made depending upon the drug used to fill the capsule.

The particular elastomer and solvent employed for a given drug are chosen in accordance with the criteria set forth above for the drug-solvent-elastomer system. Commonly employed solvents and carrier liquids useful in the present invention include glycols, such as propylene glycol; glycerol; selected animal fats; hydrogenated vegetable oils; mineral oil; silicone oils and mixtures thereof. Silicone oils include not only the common homopolymers poly [dimethyl siloxane], but also the homopolymers poly [diphenyl siloxane], poly [methyl phenyl siloxane], poly [methy], B-carboxyethyl siloxane and random copolymers and interpolymers based on the mer units of the above stated homopolymers. Colloidal silica may conveniently be used as a thickening agent to maintain dispersion of suspended drug, above or in combination with polymeric additives to assist in maintaing dispersion.

The following example illustrates the present invention and is not intended to limit the same.

EXAMPLE I A cylindrical capsule of the form shown in FIG. 1 having an internal diameter of 0.600 cm. and an internal length of [.2 cm. is formed by IIIJCCDOI'I molding from polycarbonate, with six supporting pillars, (10 in FIG. 2) equally spaced, being used as a frame on which a silicone membrane is subsequently cast. Stainless wire (20mil. diameter) is spirally wound over the six pillars so as to form a support for the silicone composition. Ends of the wire are seized by forcing them into holes drilled in the polycarbonate body above and below the membrane area, then heat sealing.

The total height of the pillars defining the membrane area is 0.40cm. A dummy plug is driven into the capsule so as to form an internal mold surface, and silicone RTV rubber of the acetoxy type is forced through the stainless steel wire and around the posts until it fills the space bonded by the dummy plug. A cellophane tape is applied externally by means of a dental clamp to support the liquid silicone, and air cure is allowed to occur for 24 hours, followed by immersion in C., water for 1 hour to extract residual acetic acid and complete hydrolysis of the silicone rubber now solidified as a membrane around the stainless steel wire, the polycarbonate posts and the upper and lower portions of the polycarbonate body.

The dummy is removed and the capsule is filled through its open end 3 (FIG. 1) with a suspension of 25 parts estrogen hormone in 75 parts dimethyl silicone oil of viscosity 1,000 centipose, thickened by part of Cubosil(TM) silica. A hollow cylinder formed of soft magnetic iron, machined and then coated with a ceramic tocover all areas, having a length of 0.60cm., an inside diameter of 0.35cm., and an outside diameter of 0.570cm. is inserted through the open end of the capsule and placed in the closed position but is over the membrane area. A tantalum spring exerting a force of 1.5 grams when fully collapsed, 0.6 grams when fully extended, is placed behind the hollow iron cylinder. A threaded end plate 3 is then screwed into the end of the capsule, eliminating all air from inside the capsule. Superficial heat sealing is used too at the external junction of the capsule body and the end plate to insure against leakage. The heat sealing is accomplished by a rapid use of a miniature gas oxygen torch to effect superficial fusion without heating the main body of the capsule.

The capsule is designed for implantation in the upper thigh, at a depth of %cm., with the end 3 nearest the surface. A 40- gram AiNiCor rod magnet taped over the skin immediately above magnet is sufficient to keep the internal hollow iron cylinder in the open position, for release of the contraceptive estrogen. Removal of the magnet allows immediate close of the membrane area from access of the estrogen-silicone oil suspension, and within 8 hours the rate of release of estrogen falls exponentially a value approximate by 5 percent of that corresponding to full open position (magnetic retraction of the hollow iron wire).

I claim:

1. A capsule suitable for implantation in the human body which comprise a wall,

end sections attached to said wall to define a closed hollow chamber,

a medicament within said chamber,

a portion of said wall being formed of a permeable crosslinked elastomeric composition,

an open hollow magnet in said chamber being movable under a magnetic force to seal or expose the permeable wall portion to the medicament,

and a spring means in said chamber between said magnet and one of said end sections biasing said magnet toward a position to effect sealing of said permeable wall portion from said chamber.

2. The capsule of claim 1 wherein the permeable wall is formed of a cross-linked silicone rubber.

3. The capsule of claim 1 wherein the permeable wall portion is provided with a reinforcing means.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3093831 *Oct 22, 1959Jun 18, 1963Jordan Gerhard Paul WilhelmArtificial gland
US3118439 *Mar 19, 1958Jan 21, 1964Jean-Pierre PerrenoudDiagnostic and medicating capsule and the method of use
US3279996 *Aug 28, 1962Oct 18, 1966Folkman Moses JudahPolysiloxane carrier for controlled release of drugs and other agents
US3315660 *Aug 8, 1963Apr 25, 1967Abella Carlos ACapsule for insertion in the digestive track
US3419008 *Feb 24, 1966Dec 31, 1968Paul J. PlishnerMagnetically actuated valve clamp for urethra control
US3485235 *Dec 4, 1967Dec 23, 1969Felson RonaldCapsule for the study and treatment of the digestive tract
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3802425 *Oct 14, 1971Apr 9, 1974Moulding TIntrauterine contraceptive device
US3840009 *Dec 27, 1971Oct 8, 1974Alza CorpSelf-powered vapor pressure delivery device
US3894538 *Aug 6, 1973Jul 15, 1975Siemens AgDevice for supplying medicines
US3903888 *Mar 11, 1974Sep 9, 1975Minnesota Mining & MfgTime-delay metering dispenser
US3951147 *Apr 7, 1975Apr 20, 1976Metal Bellows CompanyImplantable infusate pump
US4005699 *Oct 9, 1974Feb 1, 1977Louis BucaloMethods and apparatus for use in magnetic treatment of the body
US4197846 *Jun 25, 1975Apr 15, 1980Louis BucaloMethod for structure for situating in a living body agents for treating the body
US4265241 *Feb 28, 1979May 5, 1981Andros IncorporatedImplantable infusion device
US4312347 *Feb 25, 1980Jan 26, 1982Iowa State University Research Foundation, Inc.Positive pressure drug releasing device
US4507115 *Feb 28, 1984Mar 26, 1985Olympus Optical Co., Ltd.Medical capsule device
US4541429 *May 10, 1982Sep 17, 1985Prosl Frank RImplantable magnetically-actuated valve
US5019372 *Sep 7, 1990May 28, 1991The Children's Medical Center CorporationSustained release
US5170801 *Oct 2, 1990Dec 15, 1992Glaxo Inc.Medical capsule device actuated by radio-frequency (rf) signal
US5217449 *Dec 11, 1990Jun 8, 1993Miyarisan Kabushiki KaishaMedical capsule and apparatus for activating the same
US5279607 *May 30, 1991Jan 18, 1994The State University Of New YorkTelemetry capsule and process
US5395366 *Jan 10, 1994Mar 7, 1995The State University Of New YorkFor removal of a fluid sample from the alimentary canal of an animal
US6632216Dec 20, 2000Oct 14, 2003Phaeton Research Ltd.Ingestible device
US6939323 *Jul 19, 2002Sep 6, 2005Massachusetts Institute Of TechnologyNeedleless injector
US7048730 *Dec 22, 2003May 23, 2006Petrakis Dennis NTemperature activated systems
US7066922Oct 21, 2002Jun 27, 2006Massachusetts Institute Of TechnologyTransdermal transport device with suction
US7160258Jun 26, 2001Jan 9, 2007Entrack, Inc.Capsule and method for treating or diagnosing the intestinal tract
US7282045Jun 27, 2003Oct 16, 2007Phaeton Research Ltd.Ingestible device
US7287485May 19, 2006Oct 30, 2007Petrakis Dennis NTemperature activated systems
US7364568Oct 21, 2002Apr 29, 2008Massachusetts Institute Of TechnologyMicroneedle transdermal transport device
US7425204Apr 28, 2005Sep 16, 2008Massachusetts Institute Of TechnologyNeedleless injector
US7429258Sep 9, 2002Sep 30, 2008Massachusetts Institute Of TechnologyMicroneedle transport device
US7445616Mar 17, 2004Nov 4, 2008Petrakis Dennis NTemperature responsive systems
US7455668Oct 30, 2007Nov 25, 2008Petrakis Dennis NTemperature activated systems
US7476224Apr 9, 2008Jan 13, 2009Petrakis Dennis NTemperature responsive systems
US7497856 *Aug 11, 2005Mar 3, 2009Fachhochschule JenaArrangement for remote-controlled release of active ingredients
US7530975Sep 8, 2003May 12, 2009Massachusetts Institute Of TechnologyMeasuring properties of an anatomical body
US7607402Nov 20, 2007Oct 27, 2009Petrakis Dennis NTemperature responsive systems
US7645263Oct 21, 2002Jan 12, 2010Massachusetts Institute Of TechnologyImpedance sensor
US7651475Jan 11, 2008Jan 26, 2010Massachusetts Institute Of TechnologyMicroneedle transport device
US7655001Sep 29, 2008Feb 2, 2010Petrakis Dennis NTemperature responsive systems
US7763014Jul 30, 2007Jul 27, 2010Phaeton Research Ltd.Ingestible device
US7824347May 1, 2003Nov 2, 2010Entrack, Inc.System for marking a location for treatment within the gastrointestinal tract
US8005536Dec 22, 2003Aug 23, 2011Entrack, Inc.Capsule and method for treating or diagnosing conditions or diseases of the intestinal tract
US8048044 *Aug 11, 2008Nov 1, 2011Stryker CorporationDrug delivery system
US8061006 *Jul 25, 2002Nov 22, 2011Powderject Research LimitedParticle cassette, method and kit therefor
US8105270May 12, 2009Jan 31, 2012Massachusetts Institute Of TechnologyMeasuring properties of an anatomical body
US8172458Sep 29, 2008May 8, 2012Petrakis Dennis NTemperature responsive systems
US8246582Apr 29, 2008Aug 21, 2012Massachusetts Institute Of TechnologyMicroneedle transdermal transport device
US8360976Dec 22, 2003Jan 29, 2013Entrack, Inc.Optical capsule and spectroscopic method for treating or diagnosing the intestinal tract
US8414559May 7, 2009Apr 9, 2013Rainbow Medical Ltd.Gastroretentive duodenal pill
US8517961Nov 1, 2010Aug 27, 2013Entrack, Inc.System for marking a location for treatment within the gastrointestinal tract
US8758271Aug 31, 2010Jun 24, 2014Massachusetts Institute Of TechnologyNonlinear system identification techniques and devices for discovering dynamic and static tissue properties
US20130053928 *May 31, 2012Feb 28, 2013Daniel GatDevice, system and method for in vivo light therapy
DE3316934A1 *May 9, 1983Nov 10, 1983Infusaid CorpImplantierbares ventil
EP1398052A2 *Dec 14, 2000Mar 17, 2004Phaeton Research LtdIngestible device for the release of substances at distinct locations in the alimentary canal
EP1435920A1 *Aug 30, 2002Jul 14, 2004Durect CorporationFlow regulator
WO1980001755A1 *Feb 25, 1980Sep 4, 1980Andros IncImplantable infusion device
WO2001045789A2 *Dec 14, 2000Jun 28, 2001Peter Hanson HirstIngestible device for the release of substances at distinct locations in the alimentary canal
WO2004093942A2 *Mar 17, 2004Nov 4, 2004Petrakis Dennis NTemperature responsive systems
Classifications
U.S. Classification604/891.1, 604/288, 604/131, 604/249
International ClassificationA61M31/00
Cooperative ClassificationA61M31/002
European ClassificationA61M31/00D
Legal Events
DateCodeEventDescription
May 8, 1986AS02Assignment of assignor's interest
Owner name: CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUS
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, 300 LON
Effective date: 19860424
May 8, 1986ASAssignment
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, 300 LON
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122
Effective date: 19860424
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHARLES RIVER FOUNDATION THE, A MA. EQUITABLE TRUST;REEL/FRAME:004548/0122
Owner name: CHILDREN S MEDICAL CENTER CORPORATION THE, MASSACH